title: CD40 Generation 2.5 Antisense Oligonucleotide Treatment Attenuates Doxorubicin-induced Nephropathy and Kidney Inflammation.
abstract: Preclinical and clinical data suggest CD40 activation contributes to renal inflammation and injury. We sought to test whether upregulation of CD40 in the kidney is a causative factor of renal pathology and if reduction of renal CD40 expression, using antisense oligonucleotides (ASOs) targeting CD40, would be beneficial in mouse models of glomerular injury and unilateral ureter obstruction. Administration of a Generation 2.5 CD40 ASO reduced CD40 mRNA and protein levels 75-90% in the kidney. CD40 ASO treatment mitigated functional, transcriptional, and pathological endpoints of doxorubicin-induced nephropathy. Experiments using an activating CD40 antibody revealed CD40 is primed in kidneys following doxorubicin injury or unilateral ureter obstruction and CD40 ASO treatment blunted CD40-dependent renal inflammation. Suborgan fractionation and imaging studies demonstrated CD40 in glomeruli before and after doxorubicin administration that becomes highly enriched within interstitial and glomerular foci following CD40 activation. Such foci were also sites of ASO distribution and activity and may be predominately comprised from myeloid cells as bone marrow CD40 deficiency sharply attenuated CD40 antibody responses. These studies suggest an important role of interstitial renal and/or glomerular CD40 to augment kidney injury and inflammation and demonstrate that ASO treatment could be an effective therapy in such disorders.
authors.affiliation: Antisense Drug Discovery, Isis Pharmaceuticals, Inc., Carlsbad, California, USA.
authors.forename: Aaron J
authors.initials: AJ
authors.lastname: Donner
authors.affiliation: Antisense Drug Discovery, Isis Pharmaceuticals, Inc., Carlsbad, California, USA.
authors.forename: Steve T
authors.initials: ST
authors.lastname: Yeh
authors.affiliation: Antisense Drug Discovery, Isis Pharmaceuticals, Inc., Carlsbad, California, USA.
authors.forename: Gene
authors.initials: G
authors.lastname: Hung
authors.affiliation: Antisense Drug Discovery, Isis Pharmaceuticals, Inc., Carlsbad, California, USA.
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Graham
authors.affiliation: Antisense Drug Discovery, Isis Pharmaceuticals, Inc., Carlsbad, California, USA.
authors.forename: Rosanne M
authors.initials: RM
authors.lastname: Crooke
authors.affiliation: Antisense Drug Discovery, Isis Pharmaceuticals, Inc., Carlsbad, California, USA.
authors.forename: Adam E
authors.initials: AE
authors.lastname: Mullick